Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma

Surgery

Volumn 147, Issue 6, 2010, Pages 847-853

  Cheng, Shih Ping ^a,c   Chi, Chin Wen ^a,b   Tzen, Chi Yuan ^c,d   Yang, Tsen Long ^c,d   Lee, Jie Jen ^c,e   Liu, Tsang Pai ^c,d   Liu, Chien Liang ^c,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; LEPTIN RECEPTOR;

ADULT; ARTICLE; CANCER SIZE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID PAPILLARY CARCINOMA;

ADULT; BODY MASS INDEX; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEPTIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECEPTORS, LEPTIN; THYROID NEOPLASMS;

EID: 77952320543     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.11.004     Document Type: Article

References (39)

1. Chen A.Y., Jemal A., and Ward E.M. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115 (2009) 3801-3807
2. Hay I.D., Thompson G.B., Grant C.S., et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26 (2002) 879-885
3. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., et al. American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
4. Lundgren C.I., Hall P., Dickman P.W., and Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 106 (2006) 524-531
5. Mazzaferri E.L., Doherty G.M., and Steward D.L. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 19 (2009) 683-689
6. Phitayakorn R., Super D.M., and McHenry C.R. An investigation of epidemiologic factors associated with large nodular goiter. J Surg Res 133 (2006) 16-21
7. Dal Maso L., Bosetti C., La Vecchia C., and Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 20 (2009) 75-86
8. Brindel P., Doyon F., Rachédi F., Boissin J.L., Sebbag J., Shan L., et al. Anthropometric factors in differentiated thyroid cancer in French Polynesia: a case-control study. Cancer Causes Control 20 (2009) 581-590
9. Calle E.E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (2004) 579-591
10. Bergstrom A., Pisani P., Tenet V., Wolk A., and Adami H.O. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91 (2001) 421-430
11. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
12. Schwartz M.W., Peskind E., Raskind M., Boyko E.J., and Porte Jr. D. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 2 (1996) 589-593
13. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83 (1995) 1263-1271
14. Garofalo C., and Surmacz E. Leptin and cancer. J Cell Physiol 207 (2006) 12-22
15. Yuan S.S., Tsai K.B., Chung Y.F., Chan T.F., Yeh Y.T., Tsai L.Y., et al. Aberrant expression and possible involvement of the leptin receptor in endometrial cancer. Gynecol Oncol 92 (2004) 769-775
16. Koda M., Sulkowska M., Wincewicz A., Kanczuga-Koda L., Musiatowicz B., Szymanska M., et al. Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer. Ann N Y Acad Sci 1095 (2007) 90-98
17. Paik S.S., Jang S.M., Jang K.S., Lee K.H., Choi D., and Jang S.J. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16 (2009) 297-303
18. Ishikawa M., Kitayama J., and Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10 (2004) 4325-4331
19. Garofalo C., Koda M., Cascio S., Sulkowska M., Kanczuga-Koda L., Golaszewska J., et al. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 12 (2006) 1447-1453
20. Hong S.J., Kwon K.W., Kim S.G., Ko B.M., Ryu C.B., Kim Y.S., et al. Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine 33 (2006) 66-71
21. Zhao X., Huang K., Zhu Z., Chen S., and Hu R. Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer. J Gastroenterol Hepatol 22 (2007) 1317-1321
22. Wang X.J., Yuan S.L., Lu Q., Lu Y.R., Zhang J., Liu Y., et al. Potential involvement of leptin in carcinogenesis of hepatocellular carcinoma. World J Gastroenterol 10 (2004) 2478-2481
23. Wang S.N., Chuang S.C., Yeh Y.T., Lu Y.R., Zhang J., Liu Y., et al. Potential prognostic value of leptin receptor in hepatocellular carcinoma. J Clin Pathol 59 (2006) 1267-1271
24. Vona-Davis L., and Rose D.P. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14 (2007) 189-206
25. Sharma D., Saxena N.K., Vertino P.M., and Anania F.A. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 13 (2006) 629-640
26. Attoub S., Noe V., Pirola L., Bruyneel E., Chastre E., Mareel M., et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J 14 (2000) 2329-2338
27. Gonzalez R.R., Cherfils S., Escobar M., Yoo J.H., Carino C., Styer A.K., et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 281 (2006) 26320-26328
28. Chen C., Chang Y.C., Liu C.L., Liu T.P., Chang K.J., and Guo I.C. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr Relat Cancer 14 (2007) 513-529
29. Yuan S.S., Chung Y.F., Chen H.W., Tsai K.B., Chang H.L., Huang C.H., et al. Aberrant expression and possible involvement of the leptin receptor in bladder cancer. Urology 63 (2004) 408-413
30. Isozaki O., Tsushima T., Nozoe Y., Miyakawa M., and Takano K. Leptin regulation of the thyroids: negative regulation on thyroid hormone levels in euthyroid subjects and inhibitory effects on iodide uptake and Na+/I- symporter mRNA expression in rat FRTL-5 cells. Endocr J 51 (2004) 415-423
31. Frankenberry K.A., Somasundar P., McFadden D.W., and Vona-Davis L.C. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 188 (2004) 560-565
32. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67 (2007) 2497-2507
33. Jaffe T., and Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer 123 (2008) 2543-2556
34. Yang S.N., Chen H.T., Tsou H.K., Huang C.Y., Yang W.H., Su C.M., et al. Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor. Carcinogenesis 30 (2009) 566-574
35. Horiguchi A., Sumitomo M., Asakuma J., Asano T., Zheng R., Asano T., et al. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol 176 (2006) 1631-1635
36. Koo B.S., Choi E.C., Yoon Y.H., Kim D.H., Kim E.H., and Lim Y.C. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Ann Surg 249 (2009) 840-844
37. Myers M.G., Cowley M.A., and Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70 (2008) 537-556
38. Freedland S.J., Grubb K.A., Yiu S.K., Humphreys E.B., Nielsen M.E., Mangold L.A., et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 174 (2005) 919-922
39. Fleming J.B., Gonzalez R.J., Petzel M.Q., Lin E., Morris J.S., Gomez H., et al. Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg 144 (2009) 216-221